Organon Completes Global MIUDELLA® Licensing Agreement
JERSEY CITY, N.J., June 22, 2026 Organon has completed a global licensing agreement with Sebela Pharmaceuticals for MIUDELLA®, a...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
JERSEY CITY, N.J., June 22, 2026 Organon has completed a global licensing agreement with Sebela Pharmaceuticals for MIUDELLA®, a...
LONDON, United Kingdom, June 18, 2026 LabGenius Therapeutics and LG Chem have entered into a multi-year research collaboration, option,...
INCHEON, South Korea & KIRKLAND, Quebec, Canada, June 18, 2026 Samsung Bioepis and Organon have expanded their long-standing biosimilar...
SHANGHAI, China & JERSEY CITY, N.J., April 29, 2026 Shanghai Henlius Biotech, Inc. and Organon have announced that the...
Jersey City, New Jersey, U.S. | April 15, 2026 Organon has announced that its VTAMA® (tapinarof) cream, 1% has...
